Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
James R SeiboldToby M MaherKristin B HighlandShervin AssassiArata AzumaLaura Kathleen HummersUlrich CostabelUte von WangenheimVeronika KohlbrennerMartina GahlemannMargarida AlvesOliver Distlernull nullPublished in: Annals of the rheumatic diseases (2020)
The adverse event profile of nintedanib in patients with SSc-ILD is consistent with its established safety and tolerability profile in patients with idiopathic pulmonary fibrosis. Dose adjustment is important to minimise the impact of adverse events and help patients remain on therapy.
Keyphrases
- interstitial lung disease
- idiopathic pulmonary fibrosis
- systemic sclerosis
- rheumatoid arthritis
- end stage renal disease
- open label
- newly diagnosed
- chronic kidney disease
- clinical trial
- ejection fraction
- phase iii
- study protocol
- phase ii
- emergency department
- peritoneal dialysis
- prognostic factors
- stem cells
- randomized controlled trial
- patient reported outcomes
- double blind
- bone marrow
- patient reported
- artificial intelligence